NSE PPLPHARMA · BSE 543635 · Biotechnology & Drugs · NIFTY 500
Piramal Pharma Share Price
Piramal Pharma Overview
Where the price stands, how it has moved and how it sits against its averages.
Piramal Pharma shares last traded at ₹208.47 on the NSE, down 1.26% on the day. That is 10.1% below the 52-week high of ₹231.85 and 57.3% above the 52-week low of ₹132.50. Its market value is ₹27,692 Cr.
Price returns
Against the market: 1 Month ▲ +3.26% · 3 Months ▲ +25.74% · 6 Months ▲ +50.28% · This year ▲ +39.37% · 1 Year ▲ +15.60%
Shading grows with the size of the move. Prices refresh every 15 minutes while the market is open (9:15 AM–3:30 PM IST); next update from Mon 28 Sep, 9:15 AM.
Moving averages — price is above 4 of 6
- 20-day average₹212.72 ▼ price 2.0% below
- 10-day average₹211.20 ▼ price 1.3% below
- Today's price₹208.47
- 5-day average₹208.00 ▲ price 0.2% above
- 50-day average₹203.57 ▲ price 2.4% above
- 100-day average₹186.96 ▲ price 11.5% above
- 300-day average₹173.88 ▲ price 19.9% above
Averages above today's price sit higher on the ladder. Price above most of its averages is usually read as an upward trend.
Piramal Pharma Financial Results
Revenue and net profit in ₹ crore, with the full statements underneath.
Year by year
| Fiscal year | Revenue | Growth | Net profit | Net margin | EPS | Dividend |
|---|---|---|---|---|---|---|
| FY 2026 | ₹8,869 Cr | ▼ −3.1% | −₹326 Cr | −3.7% | −₹2.46 | ₹0.00 |
| FY 2025 | ₹9,151 Cr | ▲ +12.0% | ₹91 Cr | 1.0% | ₹0.68 | ₹0.14 |
| FY 2024 | ₹8,171 Cr | ▲ +15.4% | ₹18 Cr | 0.2% | ₹0.14 | ₹0.11 |
| FY 2023 | ₹7,082 Cr | ▲ +8.0% | −₹186 Cr | −2.6% | −₹1.53 | — |
| FY 2022 | ₹6,559 Cr | ▲ +123.2% | ₹376 Cr | 5.7% | ₹3.11 | ₹0.00 |
| FY 2021 | ₹2,939 Cr | — | ₹572 Cr | 19.4% | ₹4.71 | ₹0.00 |
Quarter by quarter
| Quarter | Revenue | vs prev. qtr | Net profit | Net margin | EPS |
|---|---|---|---|---|---|
| Q1 FY27 | ₹2,270 Cr | ▼ −17.5% | −₹69 Cr | −3.1% | −₹0.52 |
| Q4 FY26 | ₹2,752 Cr | ▲ +28.6% | −₹9 Cr | −0.3% | −₹0.07 |
| Q3 FY26 | ₹2,140 Cr | ▲ +4.7% | −₹136 Cr | −6.4% | −₹1.03 |
| Q2 FY26 | ₹2,044 Cr | ▲ +5.7% | −₹99 Cr | −4.9% | −₹0.75 |
| Q1 FY26 | ₹1,934 Cr | ▼ −29.8% | −₹82 Cr | −4.2% | −₹0.62 |
| Q4 FY25 | ₹2,754 Cr | ▲ +24.9% | ₹154 Cr | 5.6% | ₹1.14 |
| Q3 FY25 | ₹2,204 Cr | ▼ −1.7% | ₹4 Cr | 0.2% | ₹0.03 |
| Q2 FY25 | ₹2,242 Cr | — | ₹23 Cr | 1.0% | ₹0.17 |
Balance sheet — FY26
- Total assets₹17,965 Cr
- Total liabilities₹9,802 Cr
- Shareholders' equity₹8,163 Cr
- Total debt₹5,675 Cr
- Cash & investments₹1,332 Cr
- Current ratio1.51×
- Revenue growth, 5 yr24.72% a year
- Operating margin (TTM)−0.70%
- Net margin (TTM)−3.41%
Cash flow — FY26
Right of the line = cash coming in, left = cash going out. Free cash flow = cash from operations minus capital spending.
Full financial statements, FY21–FY26
| ₹ crore | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Total revenue | 2,938.81 | 6,559.10 | 7,081.55 | 8,171.16 | 9,151.18 | 8,869.08 |
| Cost of revenue | 1,227.76 | 2,614.80 | 2,911.11 | 3,195.59 | 3,498.81 | 3,498.72 |
| Gross profit | 1,711.05 | 3,944.30 | 4,170.44 | 4,975.57 | 5,652.37 | 5,370.36 |
| Operating expenses | 1,844.83 | 5,264.90 | 5,937.62 | 6,683.37 | 8,442.52 | 8,868.83 |
| Operating income | 1,093.98 | 1,294.20 | 1,143.93 | 1,487.79 | 708.66 | 0.25 |
| Depreciation | 143.64 | 586.18 | 676.69 | 740.57 | 771.59 | 824.26 |
| Profit before tax | 686.78 | 484.98 | −120.15 | 179.29 | 414.64 | −176.06 |
| Tax | 115.28 | 109.02 | 66.31 | 161.47 | 323.51 | 149.88 |
| Net profit | 571.50 | 375.96 | −186.46 | 17.82 | 91.13 | −325.94 |
| EPS (₹) | 4.71 | 3.11 | −1.53 | 0.14 | 0.68 | −2.46 |
| Dividend per share (₹) | 0.00 | 0.00 | — | 0.11 | 0.14 | 0.00 |
| ₹ crore | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Total assets | 5,756.67 | 12,797.04 | 14,522.56 | 15,311.81 | 15,677.59 | 17,965.04 |
| Current assets | 1,767.50 | 4,067.22 | 4,835.48 | 5,464.47 | 5,796.99 | 7,191.66 |
| Cash & short-term investments | 252.63 | 282.42 | 626.46 | 501.51 | 388.54 | 1,331.66 |
| Inventory | 420.68 | 1,521.19 | 1,812.71 | 2,296.41 | 2,453.50 | 3,251.58 |
| Property, plant & equipment | 1,384.57 | 3,715.74 | 4,441.45 | 4,815.97 | 5,023.49 | 5,641.85 |
| Total liabilities | 1,656.05 | 6,100.44 | 7,749.06 | 7,400.44 | 7,552.12 | 9,802.42 |
| Current liabilities | 1,471.67 | 3,033.34 | 3,843.05 | 4,369.30 | 3,766.27 | 4,758.28 |
| Total debt | 174.26 | 4,127.92 | 5,637.08 | 4,710.16 | 4,856.47 | 5,674.59 |
| Total equity | 4,100.62 | 6,696.60 | 6,773.50 | 7,911.37 | 8,125.47 | 8,162.62 |
| ₹ crore | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| From operations | 34.72 | 843.16 | 483.89 | 1,004.54 | 892.30 | 1,652.59 |
| From investing | −4,382.89 | −1,812.10 | −1,338.78 | −434.01 | −477.46 | −826.03 |
| From financing | 4,494.16 | 794.19 | 817.79 | −422.36 | −440.83 | −38.98 |
| Capital expenditure | −58.11 | −889.51 | −964.75 | −712.04 | −664.38 | −890.02 |
| Dividends paid | — | −50.00 | −67.00 | 0.00 | −14.47 | −18.55 |
| Net change in cash | 145.99 | −176.79 | −31.95 | 165.96 | −36.87 | 793.93 |
What Analysts Say
Recommendations from 9 analysts who cover Piramal Pharma.
▲ 9 bullish (100.0%) · 0 hold (0.0%) · ▼ 0 bearish (0.0%)
Votes
How the votes changed
| Rating | 3M ago | 2M ago | 1M ago | 1W ago | Now | 3-month change |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | — |
| Buy | 4 | 4 | 4 | 4 | 4 | — |
| Hold | 0 | 0 | 0 | 0 | 0 | — |
| Sell | 0 | 0 | 0 | 0 | 0 | — |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | — |
Analyst ratings are opinions, not a guarantee of returns.
Piramal Pharma vs Peers
Side by side with other biotechnology & drugs companies. The small bars compare each column.
| Company | Price | Change | Market cap | P/E | P/B | ROE (5 yr) | Net margin | Div. yield | Rating |
|---|---|---|---|---|---|---|---|---|---|
| Piramal Pharma | ₹208.47 | ▼ −1.26% | ₹27,692 Cr | — | 3.43 | −0.08% | −3.41% | 0.00% | This stock |
| Sun Pharmaceutical Industries | ₹1,853.00 | ▼ −0.64% | ₹4,44,586 Cr | 38.40 | 5.55 | 14.22% | 19.12% | 0.83% | Moderately Bearish |
| Divi's Laboratories | ₹9,613.00 | ▲ +0.17% | ₹2,55,195 Cr | 73.32 | 11.48 | 16.87% | 24.32% | 0.41% | Bullish |
| Torrent Pharmaceuticals | ₹4,935.00 | ▼ −0.90% | ₹1,87,705 Cr | 72.73 | 19.22 | 23.00% | 15.29% | 0.80% | Bullish |
| Cipla | ₹1,404.00 | ▲ +1.74% | ₹1,13,423 Cr | 27.57 | 3.33 | 14.47% | 13.74% | 0.92% | Neutral |
| Zydus Lifesciences | ₹1,180.00 | ▲ +0.90% | ₹1,17,705 Cr | 21.19 | 4.24 | 17.90% | 18.51% | 0.09% | Bullish |
Rating = the data provider's overall technical view of each peer. Company names link to their own pages.
Piramal Pharma Key Metrics
Each ratio placed against a benchmark — the sector average, the company's own 5-year average, or a common rule of thumb.
Valuation Is the price reasonable?
Profitability Of every ₹100 of sales, how much is kept?
Returns & efficiency How well does it use its money?
Growth Is the business getting bigger?
Financial strength Can it pay its bills and debts?
Per share What each share stands for
The share price is 3.39× the book value behind each share.
Benchmarks: sector averages and 5-year averages come from the data provider; the debt and liquidity bands are common rules of thumb, not investment advice.
All 92 metrics from the data provider
Valuation
Per share
Margins
Growth
Financial strength
Returns & efficiency
Price & volume
Dividends & Corporate Events
Payouts to shareholders, splits and bonus issues, and company meetings — newest first.
- Dividend yield0.00%
- Latest dividend₹0.11 per share · 12 Jul 2024
Corporate calendar
- MeetingAnnual General Meeting
- BoardQuarterly Results
- BoardAudited Results
- BoardQuarterly Results
- MeetingPostal Ballot
- BoardQuarterly Results
- BoardQuarterly Results
- BoardAudited Results & Final Dividend
Show 8 older events
- MeetingPostal Ballot
- BoardQuarterly Results
- BoardQuarterly Results
- MeetingAnnual General Meeting
- Dividend₹0.11 per share · 1% · Final dividend
- RightsRights issue of equity shares of ₹ 10/- in the ratio of 5:46 @ premium of ₹ 71/-.
- MeetingAnnual General Meeting
- MeetingPostal Ballot
About Piramal Pharma
Biotechnology & Drugs
Piramal Pharma Limited is a global pharmaceutical company, which offers a portfolio of differentiated pharma products across a domestic and global distribution network. It operates approximately 17 development and manufacturing facilities across India, the United Kingdom/Europe, and North America. It has a commercial presence in over 100 countries. The Company operates under three business verticals: Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization (CDMO); Piramal Critical Care (PCC), a Complex Hospital Generics (CHG) business; and Piramal Consumer Healthcare business, selling over-the-counter products. PPS caters to both drug substances - Active Pharmaceutical Ingredients (APIs), and drug products (formulations). PCC's complex hospital product portfolio comprises hospital-focused products in the areas of inhalation anesthesia, intrathecal therapy, injectable anesthesia and pain management, and other generic and specialty products.
Key people
- Nandini A. PiramalExecutive Chairman of the Board
- Vivek ValsarajChief Financial Officer, Executive Director
- Maneesh SharmaCompliance Officer, Company Secretary
- Peter DeYoungExecutive Director, Chief Executive Officer of Global Pharma
Company facts
- NSE symbolPPLPHARMA
- BSE code543635
- ISININE0DK501011
- IndustryBiotechnology & Drugs
- IndexNIFTY 500
- Market cap₹27,692 Cr
- Revenue (FY26)₹8,869 Cr
- Net profit (FY26)−₹326 Cr
In the News
Recent headlines about Piramal Pharma — they open on Mint in a new tab.
- Stock market today: Trade guide for Sensex, Nifty 50, crude oil to gold | Eight stocks to buy
Stock market today: Indian stock market indices Sensex and Nifty 50 are set for a lower open on 8 September amid mixed global cues. Nifty 50 closed below 23,800, signaling bearish momentum, while elevated crude oil prices and geopolitical tensions raise concerns over inflation and market sentiment.
8 Sep 2026 · 5 min read · Mint ↗ - Buy or sell: Gift Nifty hints at a volatile session, Vaishali Parekh recommends three stocks to buy today — 19 August
Buy or sell: Vaishali Parekh recommends three stocks to buy today — Data Patterns, L&T Finance, and Piramal Pharma
19 Aug 2026 · 2 min read · Mint ↗ - Stock market today: Gift Nifty hints a weak start; eight day trading stocks to buy on Tuesday, 11 August
Indian stock markets are set to open weak due to rising Brent crude prices affecting investor sentiment. The Gift Nifty indicates a negative start, while concerns over US-Iran negotiations add to market volatility and cautious trading in equities persists.
11 Aug 2026 · 4 min read · Mint ↗ - Mint Sustainability Impact Summit 2026: the new economics of responsibility
The Mint Sustainability Impact Summit 2026 will address the evolving landscape of sustainability amid geopolitical tensions and AI's rise. It will explore how businesses can balance decarbonization, competitiveness and resilience while facing escalating climate risks and energy security concerns.
29 Jul 2026 · 4 min read · Mint ↗ - Stocks to buy or sell: Dharmesh Shah of ICICI Sec suggests buying Piramal Pharma on 20 July
Indian stock indices faced losses on 20 July as HDFC Bank's disappointing earnings pressured the market. The BSE Sensex dropped 0.72%. Additionally, rising crude oil prices due to escalating Middle East tensions contributed to negative investor sentiment across sectors.
20 Jul 2026 · 3 min read · Mint ↗ - Stocks to buy or sell: Dharmesh Shah of ICICI Sec suggests buying Shriram Finance, Piramal Pharma shares on 6 July
Indian benchmark indices, Sensex and Nifty 50, opened higher on July 6, driven by gains in private banking stocks following strong quarterly updates from HDFC Bank and Axis Bank. Market breadth was positive with 14 of the 16 major indices in the green.
6 Jul 2026 · 3 min read · Mint ↗ - Depth over breadth: Piramal Consumer Healthcare takes a leaf out of the modern FMCG playbook
The company is cutting new product launches by half and doubling down on quick commerce to chase a $200 million revenue target by 2030, CEO Sai Ramana Ponugoti told Mint.
28 Jun 2026 · 3 min read · Mint ↗ - Top Gainers & Losers on June 23: Vedanta, Hindustan Zinc, Infosys, TCS, Bank of Baroda among top losers
The Indian stock market fell sharply on June 23, influenced by global market weakness and a retreat in technology stocks. The Nifty 50 declined 1.16%, marking its biggest drop in nearly four weeks, with all sectoral indices closing lower amid profit-booking and a stronger US dollar.
23 Jun 2026 · 3 min read · Mint ↗
Stock data comes from the exchange feed via our data provider and may be delayed. It is for information only and is not a recommendation to buy or sell. See all stocks →